Cohesion Bureau’s Post

🚀 Presenting ADC Digest for March 2024! 🚀 Exciting developments this week in the Antibody Drug Conjugate space: 🏅 Hengrui Medicine’s SHR-A1912 ADC receives Fast Track Designation from the FDA, paving the way for accelerated development and potential breakthroughs in cancer treatment 🚀 Mabwell's ADC, 9MW2821 targeting Nectin-4 receives Fast Track Designation from the FDA for advanced esophageal squamous cell carcinoma 💡 Nona Biosciences and Boostimmune unite to advance cutting-edge ADC development, enhancing innovation and moving closer to groundbreaking therapies Stay tuned for more groundbreaking updates in the world of ADCs! 💡 #ADCNews #MedicalBreakthroughs #InnovationInHealthcare #FDAFastTrack #CancerResearch #BiotechAdvancements #AntibodyDrugConjugate #ADCdigest #CIScientists #competitiveintelligence

🚀 Presenting ADC Digest for March 2024! 🚀 Exciting advancements unfolding this week in the Antibody Drug Conjugate Space 🔬💊 🌍Pfizer’s ADC inotuzumab ozogamicin gained FDA approval for use in pediatric patients with acute lymphoblastic leukemia 🌍Akari Therapeutics and Peak Bio merge to expand pipeline with Novel ADC Toolkit 🔬 🌍EMA grants dual validation for Daiichi Sankyo and AstraZeneca’s Cancer ADC 🌟  🌍Gilead Partners with Abingworth, securing $210M, for Trodelvy Trials 💰 Stay tuned for more groundbreaking updates in the world of ADCs! #ADC #Antibodydrugconjugate #antibodydrugconjugates #ADCnews #CIScientists #CompetitiveIntelligence #FDA #EMA

Are you attending #CEBioForum2024? Don't miss the chance to meet Dr. Tomasz Rygiel, Chief Scientific Officer at Cellis. Dr. Rygiel will be available to discuss our breakthrough platform technology, the Macrophage Drug Conjugate (MDC), for the treatment of solid tumors. Drop a comment below to schedule a meeting with Dr. Rygiel or simply connect! #CEBioForum #Warsaw #Biotechnology #CancerTreatment #MacrophageDrugConjugate #ClinicalTrials

Faron invited us to present at their capital markets day yesterday, it was a great opportunity to present our market research to Faron's investors and showcase some of our work in a public forum. We have been working with Faron to try to help them understand the #KOL perspectives, #pricing and #marketaccess barriers and the number of patients that their product #bexmarilimab will be able to treat. I love my job, I guess not many people can say that. I get to work with people at the absolute cutting edge of science, people innovating to try to cure cancers. I get to help them advance this science and hopefully save patients' lives. However, it is sometimes a shame that our work can't be made public as it is often so commercially sensitive. So its it opportunities where we get to show our work that are really exciting. You can watch the webcast here: https://lnkd.in/em9NTnaj And you will be able to see the presentation and example of our work here: https://lnkd.in/ee4w3cAk

I am delighted to present our current research to #RSCposter The poster presents work on the development of a novel pyrroloquinoxaline fluorescent probe for the selective detection of Cu2+ ions, highlighting its potential applications in healthcare environments and the pharmaceutical field. The probe's selectivity for Cu2+ was demonstrated through its successful imaging in living cancer cells and accurate measurement in water samples, showcasing its utility in monitoring trace Cu2+ in biological and pathological processes. The synthesis involves a nucleophilic aromatic substitution followed by a reduction and a key cyclisation step. Fluorescence studies revealed the probe's sensitivity and selectivity, and the addition of EDTA confirmed the reversible nature of the Cu2+ complexation, suggesting the sensor's reusability. #RSCAnalytical #RSCEnv #RSCOrg #RSCInorg

NETs in Cancer: NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy. https://bit.ly/3xixJIx #Oncology #SolidTumors

Cell cultures play a crucial role in research, but did you know that up to 35% of them may be contaminated with mycoplasma? This contamination can wreak havoc on cell functions, leading to unreliable results and wasted time and resources.    Fortunately, MD Bioproducts has your back with our highly sensitive and specific PCR-based assay. Designed to detect a broad range of mycoplasma species in cell cultures and other biological materials, our kit delivers accurate results in just a few hours after a quick 10-minute sample preparation and run time.    Don't compromise on the integrity of your research – apply MD Bioproducts for reliable mycoplasma detection. #MDBioproducts #CellCulture #MycoplasmaDetection #PCR #ResearchMethods #biotechnology #antibodyproduction #tissues #oncology #contamination #bioreactor

Come and show your support for MARGARITA DAMAI, one of our undergraduate researchers. Join the conversation at #rscposter! Eager to participate in discussions and explore the latest developments in Chemistry.

Extracellular vesicles (EVs) are garnering immense interest for their potential in diagnostics, therapeutics, and as biomarkers for a myriad of diseases. As the research community delves deeper into the microscopic marvels of EVs, the demand for technology advancement has surged. Learn more about how innovative tools from BD Biosciences can help you accelerate your discoveries. https://lnkd.in/em_yzWTM #BDBiosciences #flowcytometry #FACS

We look forward to participate at Swiss Biotech Day in Basel! BIOEMTECH is joining the Hellenic Biocluster (HBio) mission to Swiss Biotech. We look forward to meet in person with our existing Swiss collaborators, as well as make new contacts in this emerging ecosystem. Let's discuss about #drugdiscovery, #preclinicalimaging,#theranostics and #oncology and how our technology and expertise can assist researchers and pharma companies to bring novel compounds to the clinics. #swissbiotechday #swissbiotechday2024